Search Results - "Wahl, Tanya A"

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates by Liao, John B, Gwin, William R, Urban, Renata R, Hitchcock-Bernhardt, Katie M, Coveler, Andrew L, Higgins, Doreen M, Childs, Jennifer S, Shakalia, Hania N, Swensen, Ron E, Stanton, Sasha E, Tinker, Anna V, Wahl, Tanya A, Ancheta, Richard G, McGonigle, Kathryn F, Dai, James Y, Disis, Mary L, Goff, Barbara A

“…BackgroundAnti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer…”
Get full text

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 by Ganz, Patricia A, Romond, Edward H, Cecchini, Reena S, Rastogi, Priya, Geyer, Jr, Charles E, Swain, Sandra M, Jeong, Jong-Hyeon, Fehrenbacher, Louis, Gross, Howard M, Brufsky, Adam M, Flynn, Patrick J, Wahl, Tanya A, Seay, Thomas E, Wade, 3rd, James L, Biggs, David D, Atkins, James N, Polikoff, Jonathan, Zapas, John L, Mamounas, Eleftherios P, Wolmark, Norman

“…Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and…”
Get full text

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB) by Okines, Alicia Frances Clare, Paplomata, Elisavet, Wahl, Tanya A., Wright, Gail Lynn Shaw, Sutherland, Stephanie, Jakobsen, Erik, Valdes, Frances, Chan, Arlene, Clark, Amy Sanders, Conlin, Alison Katherine, Lustberg, Maryam B., Specht, Jennifer M., Pluard, Timothy J., Zhu, Xiaofu, Krop, Ian E., Gelmon, Karen A., Slamon, Dennis J., Ramos, Jorge, An, Grace, Hamilton, Erika Paige

“…Abstract only 1043 Background: Tucatinib (TUC) is an investigational TKI, highly selective for HER2 without significant inhibition of EGFR. HER2CLIMB is a…”
Get full text

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer by Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., Minckwitz, Gunter von, Mano, Max S., Untch, Michael, Huang, Chiun-Sheng, Rastogi, Priya, Conte, Pier Franco, D'hondt, Veronique, Redondo, Andres, Stamatovic, Ljiljana, Bonnefoi, Herve R., Castro Salguero, Hugo Raul, Fischer, Hans Holger, Wahl, Tanya A., Song, Chunyan, Blotner, Steven, Trask, Peter, Geyer, Charles E.

“…Abstract only 513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free…”
Get full text

Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results by Liao, John B., Gwin, William Rayford, Urban, Renata, Hitchcock-Bernhardt, Katie, Coveler, Andrew L., Higgins, Doreen, Childs, Jennifer S, Shakalia, Hania, Stanton, Sasha E., Tinker, Anna, Wahl, Tanya A., Ancheta, Richard G., McGonigle, Kathryn F., Dai, James, Disis, Mary L., Goff, Barbara Ann

“…Abstract only 5519 Background: Pembrolizumab has shown activity in advanced recurrent ovarian cancer (AOC) with an 8% response rate and median progression-free…”
Get full text

Analysis of reimbursement (R) for next generation sequencing (NGS) on patients' tumors in the context of a personalized medicine program by Brown, Thomas D., Tameishi, Mariko, Liu, Xiaoyu, Scanlan, James, Beatty, J. David, Drescher, Charles, Pagel, John M., Gold, Philip Jordan, Alexander, Shlece, Summers, Lauren K., Brindle, Madeleine, Varghis, Nina, Yates, James, Fondren, Kathleen N., Birchfield, George Richard, Dong, David Edwin, Benkers, Tara L., Wahl, Tanya A., Ramsey, Scott David, Berry, Anna Belinda

“…Abstract only 6506 Background: R policies for NGS testing vary widely among private and public insurers. While drug costs are the greatest challenge in…”
Get full text

A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients by Rivkin, Saul E., Iriarte, Desiree, Sloan, Heather, Wiseman, Cara, Moon, James, Goodman, Gary E., Bondurant, Amy, Veljovich, Daniel, Jiang, Peter Y. Z., Wahl, Tanya A., Shah, Chirag, Drescher, Charles, Kaplan, Henry G., Peters, William A., Ellis, Erin, Fer, Mehmet F., Park, Min S., Johnston, Eileen

“…Abstract only…”
Get full text